Effect of Intensive Lipid-Lowering Therapy on Coronary Plaque Stabilization Derived from Optical Coherence Tomography: a Meta-analysis and Meta-regression
ConclusionsIntensive LLT, mainly high-intensity statin therapy and combined PCSK9 antibody with statin, has a beneficial effect on coronary plaque stabilization derived from OCT in patients with CAD. Coronary plaque stabilization is primarily due to lipid-lowering effect, not anti-inflammatory effect. Moreover, the lipid-lowering effect has nothing to do with the changes in HDL-C and TG, but is mainly related to the reduction of LDL-C, TC, and ApoB. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 10, 2023 Category: Cardiology Source Type: research
SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction
AbstractResults from DELIVER trial and publication of EMPEROR-Preserved with sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure (HF) with ejection fraction (EF) > 40% represent a significant step forward in the treatment of HF with preserved EF (HFpEF). However, detailed analysis and attenuation of effect at higher EF levels have sparked some doubts about whether empagliflozin is effective across the entire spectrum of EF. HFpEF is no longer considered as one disease entity, but has been reconceptualized as a heterogenous group of phenotypes with derangements in multiple organ systems...
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial
ConclusionsThe PLINY THE ELDER trial will determine whether a lower dose of ticagrelor confers non-inferior platelet inhibition compared with the standard dose in the early phase of ACS among elderly patients undergoing PCI, informing future clinical investigation. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor
ConclusionPlatelets serve as carriers for RIC ’s cardioprotective signal through an aspirin-sensitive and thus cyclooxygenase-dependent mechanism. The P2Y12 inhibitor ticagrelor per se induces a humoral cardioprotective signal.Graphical abstract (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
Effect of PCSK9 Monoclonal Antibody Versus Placebo/Ezetimibe on Atrial Fibrillation in Patients at High Cardiovascular Risk: A Meta-Analysis of 26 Randomized Controlled Trials
ConclusionsOverall, the PCSK9 mAbs therapy reduced AF and presented certain cardiovascular benefits in patients at high cardiovascular risk. Further big-scale and long follow-up duration randomized controlled trials that compare PCSK9 mAbs with ezetimibe are required to evaluate the effect of PCSK9 mAbs versus ezetimibe on AF. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective
ConclusionCompared with ezetimibe + statins, the combination of evolocumab + statins was found to be cost-effective at a threshold of 217,341 yuan (three times per capita GDP, 2020) in patients with recent ACS events in China. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients
ConclusionAdjunctive TMZ therapy for ICM effectively improved vascular endothelial function and reduced inflammation. Furthermore, our exploratory findings may be used to provide new information on the potential effects of TMZ on myocardial fibrosis by downregulating CTGF. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
Mechanobiology of the endothelium in vascular health and disease: in vitro shear stress models
AbstractIn recent years, there has been growing evidence that vascular pathologies arise in sites experiencing an altered haemodynamic environment. Fluid shear stress (FSS) is an important contributor to vascular homeostasis and regulates endothelial cell (EC) gene expression, morphology, and behaviour through specialised mechanosensitive signalling pathways. The presence of an altered FSS profile is a pathological characteristic of many vascular diseases, with the most established example being the preferential localisation of atherosclerotic plaque development. However, the precise haemodynamic contributions to other vas...
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
Antiplatelet Therapy in End-stage Renal Disease Patients on Maintenance Dialysis: a State-of-the-art Review
AbstractPatients with end-stage renal disease (ESRD) on maintenance dialysis have an increased risk of ischaemic events, such as recurrent myocardial infarction (MI) and stroke. Potent antiplatelet therapy may help mitigate this risk. Nonetheless, ERSD patients are also at increased risk of bleeding due to their complex vascular milieu, which limits the routine use of potent P2Y12 inhibitors. Moreover, these patients are often underrepresented or excluded from major clinical trials leaving a significant gap in existing knowledge. Understanding the mechanisms of this paradox may serve as a benchmark for the development of E...
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study
ConclusionFebuxostat reduced the UA levels but did not affect the CRP levels, and therefore may fail to improve cardiovascular outcomes after treatment.Trial RegistrationClinicalTrial.gov (NCT01984749). https://clinicaltrials.gov/ct2/show/NCT01984749 (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
CircPCNX Promotes PDGF-BB-Induced Proliferation and Migration of Human Aortic Vascular Smooth Muscle Cells Through Regulating miR-1278/DNMT1 Axis
ConclusionCircPCNX promoted PDGF-BB-induced HA-VSMC proliferation and migration by elevating DNMT1 expression through sponging miR-1278. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
Considerations for Left Atrial Appendage Occlusion During Cardiac Surgery
AbstractAtrial fibrillation is associated with an increased risk of stroke secondary to thrombus formation in the left atrial appendage. Left atrial appendage occlusion (LAAO) is an effective method of reducing the risk of stroke in patients with atrial fibrillation. Although LAAO does not remove the requirement for anticoagulation, it reduces the risk of stroke when compared to anticoagulation alone. We critically analyze the data on LAAO in cardiac surgery. We also discuss the methods of LAAO, the risks of LAAO, and patient populations that could benefit from LAAO. We discuss high-level evidence that LAAO at the time of ...
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
CXCR7 Agonist TC14012 Improves Angiogenic Function of Endothelial Progenitor Cells via Activating Akt/eNOS Pathway and Promotes Ischemic Angiogenesis in Diabetic Limb Ischemia
ConclusionTC14012 can prevent EPCs from HG-induced dysfunction and apoptosis, improve eNOS activity and NO production via CXCR7/Akt signal pathway, and promote EPC mobilization and diabetic ischemia angiogenesis. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore
ConclusionOur findings suggest that concomitant use of simvastatin with rivaroxaban may be associated with bleeding events in an Asian cohort. Further studies using physiologically based pharmacokinetic modelling are required to investigate the drug-drug interactions between these drugs. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2023 Category: Cardiology Source Type: research
